Login to Your Account

BIO 2012

Pharma Summits Patent Cliff in 2012: Total $290B at Risk

By Nuala Moran
Staff Writer

Wednesday, June 20, 2012
BOSTON – 2012 may be the year that the patent cliff reaches its height – with $33 billion of sales at risk – but the impact of loss of exclusivity will continue to reverberate across the decade, with more than $290 billion of prescription drugs sales due to be exposed to generic competition between now and 2018.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription